Why the study?
Endomyocardial biopsy is the diagnostic gold standard for ATTR cardiac amyloidosis, but noninvasive clinical and paraclinical alternatives are needed when biopsy cannot be performed.
The study aims to correlate bone scintigraphy with biomarkers to aid general practitioners in diagnosing ATTR cardiac amyloidosis.
Should not yet change GP referral for ATTR-CA; extends correlation data but leaves validation open.
Transthyretin cardiac amyloidosis (ATTR) is a rare cardiac protein deposition disease characterized by progressive thickening of both ventricles, the inter-atrial-ventricular septum and the atrioventricular valves. The gold standard method for diagnosing this rare pathology is endomyocardial biopsy. If this method cannot be used, the alternative is a mixture of clinical and paraclinical tests. Over the course of five years, we examined 58 patients suspected of cardiac amyloidosis based on electrocardiography and ultrasonography criteria, who had been sent for bone scintigraphy in order to determine the presence of ATTR cardiac amyloidosis. However, the final diagnosis was set by correlating the bone scan with genetic testing, free light chain dosage or soft tissue biopsy. Based on the final diagnosis we analyzed the patients' predominant biomarkers in order to determine a possible correlation between them. This analysis is designed to help the general practitioner set a possible cardiac amyloidosis diagnosis.
No takes yet. Share an insight, caveat, or question.
Ionescu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: